stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Shares outstanding
Scholar Rock Holding Corporation's shares outstanding at the end of fiscal 2025 was $114.7M, up 14.9% from $99.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $130.6M. Over the past ten years it has ranged from $1.6M (fiscal 2016) to $114.7M (fiscal 2025) — the current reading is the highest in ten years. Scholar Rock Holding Corporation ranks 97th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $114.7M | 14.89% |
| FY2024 | $99.8M | 19.79% |
| FY2023 | $83.3M | 39.82% |
| FY2022 | $59.6M | 62.38% |
| FY2021 | $36.7M | 19.45% |
| FY2020 | $30.7M | 11.61% |
| FY2019 | $27.5M | 75.91% |
| FY2018 | $15.7M | 858.08% |
| FY2017 | $1.6M | 1.93% |
| FY2016 | $1.6M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $130.6M | 2.62% |
| Mar 2026 | $127.3M | 10.96% |
| Dec 2025 | $114.7M | 0.85% |
| Sep 2025 | $113.7M | 0.91% |
| 32 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ERAS Erasca, Inc. compare | $311.3M |
| IMVT Immunovant, Inc. compare | $205.5M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| SRRK Scholar Rock Holding Corporation | $130.6M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| MANE Veradermics Incorporated compare | $40.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement